Benitec Biopharma Inc. (BNTC)
12.52
-0.19 (-1.49%)
At close: Mar 03, 2025, 3:59 PM
12.42
-0.80%
After-hours: Mar 03, 2025, 04:00 PM EST
Company Description
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines.
The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions.
It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection.
The company was incorporated in 1995 and is headquartered in Hayward, California.
Benitec Biopharma Inc.
| Country | United States |
| IPO Date | Jun 24, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. Jerel A. Banks M.D., Ph.D. |
Contact Details
Address: 3940 Trust Way Hayward, California United States | |
| Website | https://benitec.com |
Stock Details
| Ticker Symbol | BNTC |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001808898 |
| CUSIP Number | 08205P100 |
| ISIN Number | US08205P2092 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jerel A. Banks M.D., Ph.D. | Executive Chairman & Chief Executive Officer |
| Megan Joan Boston B.Com., C.A. | Chief Financial Officer & Director |
| Sophie Mukadam | Chief Operating Officer |
| Dr. Claudia Kloth Ph.D. | Senior Vice President of Manufacturing |
| Dr. Michael Graham | Head of Discovery & Founding Scientist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 03, 2025 | 4 | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 14, 2025 | 10-Q | Quarterly Report |
| Feb 13, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 27, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 03, 2025 | 3 | Filing |
| Dec 31, 2024 | 8-K/A | [Amend] Current Report |
| Dec 26, 2024 | 4 | Filing |
| Dec 13, 2024 | 8-K | Current Report |